Aspira Pathlab accepts Vaibhav Odhekar's resignation as Additional Executive Director
Aspira Pathlab & Diagnostics Limited confirmed that Vaibhav Odhekar resigned as Additional Executive Director on July 25, 2026, due to personal reasons. The move was disclosed under SEBI LODR Regulation 30.

*this image is generated using AI for illustrative purposes only.
Aspira Pathlab & Diagnostics Limited has accepted the resignation of Vaibhav Odhekar from the position of Additional Executive Director. The change in leadership is effective from the close of business hours on July 25, 2026, with Odhekar citing personal reasons for his departure.
The company disclosed the development to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Nikunj Mange, Executive Director of Aspira Pathlab, signed the communication on July 25, 2026.
Vaibhav Odhekar, identified by DIN 05135001, submitted his resignation letter to the Board of Directors on July 25, 2026. In his letter, Odhekar expressed gratitude to the Board and management for the support extended during his tenure. He requested the Board to take necessary steps as required under applicable laws.
Resignation Details
| Particulars | Details |
|---|---|
| Name | Vaibhav Odhekar |
| DIN | 05135001 |
| Position | Additional Executive Director |
| Reason | Personal reasons |
| Effective Date | July 25, 2026 |
The filing confirms that there are no specific disclosures required regarding relationships between directors or other material conflicts related to this resignation. The brief profile section was marked as not applicable in the regulatory annexure.
Historical Stock Returns for Aspira Pathlab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.99% | +25.83% | -14.87% | +66.41% | +82.46% | +183.29% |
Will Aspira Pathlab appoint an interim Additional Executive Director or redistribute Odhekar's responsibilities among existing leadership?
How might this sudden leadership change impact investor confidence and the company's stock volatility in the short term?
Are there any pending strategic initiatives or regulatory approvals that could be delayed due to this vacancy in the executive team?


































